A Phase 3 interventional study of Tezepelumab (APFS) and Tezepelumab (AI) in Asthma, sponsored by AstraZeneca. Completed at 36 sites in 4 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-07-29.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.
Among the 28 studies testing tezepelumab in Asthma, this one is the 12th largest by enrollment, is one of 5 that started in 2019, is one of 16 in phase 3, and was the 10th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–55
AstraZeneca · Sites in China
Ages 12–80
AstraZeneca · Sites in United States, Argentina, Brazil and 19 more countries
Ages 5–11
Qianfoshan Hospital · Sites in China
Ages 18–75
Qilu Pharmaceutical Co., Ltd.
Ages 18–80
By country, each count listing its studies:
tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 5 started in 2019.
This study's enrollment of 216 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 121 across the 28 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 28 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 116th largest by enrollment of the 248 interventional ones that give a count, is one of 24 that started in 2019, is one of 121 in phase 3, and was the 255th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing tezepelumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06705764University of AlbertaTezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | 2026-11 |
| NCT07757841Qianfoshan HospitalReal-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies testing tezepelumab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, open-label, parallel-group study designed to assess healthcare provider and subject/caregiver reported functionality and performance of a single-use accessorized pre-filled syringe (APFS) or autoinjector (AI) with a fixed 210 mg dose of tezepelumab administered subcutaneously in the clinic and in an at-home setting.
The study will consist of a screening/run-in period of up to 2 weeks and a treatment period of 24 weeks, followed by a post-treatment follow-up period of 12 weeks. During the treatment period, one dose of 210 mg tezepelumab will be administered via a single-use APFS or AI subcutaneously (SC) every 4 weeks (Q4W) starting at Visit 2 (Week 0) until Visit 7 (Week 20). Subjects will be administered tezepelumab at the site during Visits 2 (Week 0), 3 (Week 4), 4 (Week 8) and 7 (Week 20). At-home administration of tezepelumab will occur during Visit 5 (Week 12) and Visit 6 (Week 16). Each device will be assessed separately using descriptive presentations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
Biological: Tezepelumab (AI)
Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
Biological: Tezepelumab (APFS)
Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
Proportions of HCPs and Subjects/Caregivers Who Successfully Administered Tezepelumab in Clinic or at Home by Device Type
Successful administration is defined as an injection completed, based on a used/returned (HCP or subject/caregiver) answer of YES to all 5 questions in the administration questionnaire, and satisfactory in vitro evaluation of returned/evaluated devices.
Time frame: Week 0, Week 4, Week 8, Week 12, Week 16, Week 20
Proportions of Used/Returned Devices That Pass Functional Tests and Visual Inspection and Showed no Evidence of Malfunction
Devices that passed functional tests and visual inspection and showed no evidence of malfunction will be evaluated as functional. Percentages have been calculated by using the number of used and returned devices at specified visit as denominator. Note: A few participants had missing devices. One participant had two AI devices at Week 4.
Time frame: Week 0, Week 4, Week 8, Week 12, Week 16, Week 20
Proportions of Devices That Have Been Reported as Malfunctioning (Product Complaints)
Performance is measured by the proportion of APFS or AI devices that have been reported as malfunctioning (i.e. via Product Complaints). Percentages have been calculated by using the number of used and returned devices at specified visit as denominator. Note: A few participants had missing devices. One participant had two AI devices at Week 4.
Time frame: Week 0, Week 4, Week 8, Week 12, Week 16, Week 20
Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score
The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.
Time frame: Baseline (Week 0), Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24
Serum Trough Concentrations
PK serum samples were collected pre-dose on dosing visits
Time frame: Baseline (Week 0), Week 4, Week 20 and Week 24 (EOT)
Anti-drug Antibodies (ADA)
Anti-drug antibodies (ADA) responses at baseline and/or post baseline. Treatment-induced ADA positive is defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive is defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following IP administration. Treatment-emergent ADA (TE-ADA) positive is defined as either treatment-induced ADA positive or treatment-boosted ADA positive. ADA incidence is the proportion of TE-ADA positive subjects in a population. Persistently positive is defined as ADA positive at \>=2 post-baseline assessments (with \>=16 weeks between first and last positive) or ADA positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive
Time frame: Pre-treatment on dosing days until end of follow-up (Week 36) per protocol
216 subjects randomized in the study.
| Milestone | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI |
|---|---|---|
| Started | 111 | 105 |
| Completed | 110 | 105 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
Successful administration is defined as an injection completed, based on a used/returned (HCP or subject/caregiver) answer of YES to all 5 questions in the administration questionnaire, and satisfactory in vitro evaluation of returned/evaluated devices.
| Participants | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI |
|---|---|---|
| Week 0 (in clinic) | 109 | 105 |
| Week 4 (in clinic) | 111 | 102 |
| Week 8 (in clinic) | 110 | 103 |
| Week 12 (at home) | 110 | 104 |
| Week 16 (at home) | 104 | 102 |
| Week 20 (in clinic) | 105 | 102 |
Devices that passed functional tests and visual inspection and showed no evidence of malfunction will be evaluated as functional. Percentages have been calculated by using the number of used and returned devices at specified visit as denominator. Note: A few participants had missing devices. One participant had two AI devices at Week 4.
| Devices | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI |
|---|---|---|
| Week 0 (in clinic) | 109 | 105 |
| Week 4 (in clinic) | 111 | 103 |
| Week 8 (in clinic) | 110 | 103 |
| Week 12 (at home) | 110 | 104 |
| Week 16 (at home) | 104 | 102 |
| Week 20 (in clinic) | 105 | 102 |
Performance is measured by the proportion of APFS or AI devices that have been reported as malfunctioning (i.e. via Product Complaints). Percentages have been calculated by using the number of used and returned devices at specified visit as denominator. Note: A few participants had missing devices. One participant had two AI devices at Week 4.
| Devices | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI |
|---|---|---|
| Week 0 (in clinic) | 2 | 0 |
| Week 4 (in clinic) | 0 | 3 |
| Week 8 (in clinic) | 0 | 2 |
| Week 12 (at home) | 0 | 0 |
| Week 16 (at home) | 3 | 0 |
| Week 20 (in clinic) | 1 | 0 |
The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.
| Score | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI |
|---|---|---|
| ACQ-6 score at Baseline (Week 0) | 2.227 ± 0.732 | 2.081 ± 0.625 |
| ACQ-6 score at Week 4 | 1.629 ± 0.791 | 1.492 ± 0.715 |
| Change from Baseline of ACQ-6 score at Week 4 | -0.598 ± 0.702 | -0.589 ± 0.694 |
| ACQ-6 score at Week 8 | 1.401 ± 0.859 | 1.316 ± 0.744 |
| Change from Baseline of ACQ-6 score at Week 8 | -0.826 ± 0.833 | -0.765 ± 0.793 |
| ACQ-6 score at Week 12 | 1.197 ± 0.751 | 1.143 ± 0.745 |
| Change from Baseline of ACQ-6 score at Week 12 | -1.011 ± 0.805 | -0.938 ± 0.805 |
| ACQ-6 score at Week 16 | 1.226 ± 0.845 | 1.171 ± 0.782 |
| Change from Baseline of ACQ-6 score at Week 16 | -0.986 ± 0.893 | -0.910 ± 0.867 |
| ACQ-6 score at Week 20 | 1.230 ± 0.832 | 1.238 ± 0.795 |
| Change from Baseline of ACQ-6 score at Week 20 | -0.978 ± 0.866 | -0.843 ± 0.910 |
| ACQ-6 score at Week 24 | 1.072 ± 0.755 | 1.140 ± 0.765 |
| Change from Baseline of ACQ-6 score at Week 24 | -1.141 ± 0.845 | -0.941 ± 0.775 |
PK serum samples were collected pre-dose on dosing visits
| µg/mL | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI |
|---|---|---|
| Baseline (Week 0) | NA ± NA | NA ± NA |
| Week 4 | 10.9764 ± 48.3948 | 10.5690 ± 57.0076 |
| Week 20 | 18.9653 ± 69.0785 | 20.3206 ± 56.5858 |
| Week 24 (EOT) | 19.6274 ± 58.2660 | 19.9264 ± 54.3198 |
Anti-drug antibodies (ADA) responses at baseline and/or post baseline. Treatment-induced ADA positive is defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive is defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following IP administration. Treatment-emergent ADA (TE-ADA) positive is defined as either treatment-induced ADA positive or treatment-boosted ADA positive. ADA incidence is the proportion of TE-ADA positive subjects in a population. Persistently positive is defined as ADA positive at \>=2 post-baseline assessments (with \>=16 weeks between first and last positive) or ADA positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive
| Participants | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI |
|---|---|---|
| ADA positive at baseline and/or post-baseline (ADA prevalence) | 2 | 11 |
| TE-ADA positive (ADA incidence) | 2 | 8 |
| Treatment-induced ADA positive | 2 | 8 |
| Treatment-boosted ADA positive | 0 | 0 |
| ADA persistently positive | 1 | 7 |
| ADA transiently positive | 1 | 3 |
| Only baseline ADA positive | 0 | 1 |
| Both baseline and at least one post-baseline ADA positive | 0 | 2 |
Collected over From first dose till end of study (Week 36). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Teze 210 mg Q4W Via APFS | 0/111 (0%) | 5/111 (4.5%) | 29/111 (26.1%) |
| Teze 210 mg Q4W Via AI | 0/105 (0%) | 4/105 (3.8%) | 29/105 (27.6%) |
| Event | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/111 | 3/105 |
| DiverticulitisInfections and infestations | 2/111 | 0/105 |
| GastritisGastrointestinal disorders | 0/111 | 1/105 |
| VaricellaInfections and infestations | 0/111 | 1/105 |
| Psychogenic seizureNervous system disorders | 0/111 | 1/105 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/111 | 1/105 |
| Pancreatitis acuteGastrointestinal disorders | 1/111 | 0/105 |
| Escherichia urinary tract infectionInfections and infestations | 1/111 | 0/105 |
| Genitourinary tract infectionInfections and infestations | 1/111 | 0/105 |
| Pneumonia escherichiaInfections and infestations | 1/111 | 0/105 |
| Event | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI |
|---|---|---|
| NasopharyngitisInfections and infestations | 12/111 | 15/105 |
| Upper respiratory tract infectionInfections and infestations | 9/111 | 8/105 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 6/111 | 5/105 |
| PharyngitisInfections and infestations | 4/111 | 4/105 |
| Age, Continuous(Years) | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI | Total |
|---|---|---|---|
| Mean | 48.5 ± 18.1 | 45.8 ± 18.3 | 47.2 ± 18.2 |
| Age, Customized(Participants) | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI | Total |
|---|---|---|---|
| Adolescents (>=12 to <18 years) | 13 | 11 | 24 |
| Adults (>=18 years) | 98 | 94 | 192 |
| Adults (>=18 to <65 years) | 79 | 73 | 152 |
| Adults (>=65 years) | 19 | 21 | 40 |
| Sex: Female, Male(Participants) | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI | Total |
|---|---|---|---|
| Female | 56 | 52 | 108 |
| Male | 55 | 53 | 108 |
| Race/Ethnicity, Customized(Participants) | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI | Total |
|---|---|---|---|
| White | 87 | 82 | 169 |
| Black or African American | 8 | 8 | 16 |
| Asian | 16 | 15 | 31 |
| Race/Ethnicity, Customized(Participants) | Teze 210 mg Q4W Via APFS | Teze 210 mg Q4W Via AI | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 13 | 25 |
| Not Hispanic or Latino | 99 | 92 | 191 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2019 to primary completion in Jun 2020, 12 months.
Results were first posted in Jul 2021, 1 year 1 month after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 12 months is below that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab